| Prev Close | 88.73 |
| Day Low/High | 87.33 / 89.09 |
| 52 Wk Low/High | 62.66 / 92.99 |
| Avg Volume | 7.52M |
AbbVie Inc. (ABBV)
87.84
NYSE : Health Technology
| Exchange | NYSE |
| Shares Outstanding | 1.48B |
| Market Cap | 131.22B |
| EPS | 3.70 |
| P/E Ratio | 38.03 |
| Div & Yield | 4.72 (4.94%) |
Earnings Growth Boosts AbbVie
Drug franchises are still going strong.
Mylan Deal Is All That Shell Is Not
The ecstasy and the agony of M&A all in one day.
Portfolio Managers Shop for Growth
Combined Heinz-Kraft heads a long second-quarter list.
Biotech, Chips Stand Their Ground
You can't help but feel better about both groups.
Biotechs Need to Rest
If there is no catalyst, I'd join those who sell on a bounce.
Backing Away From Biotechs
This sector could see some real damage.
Biotech Stocks at a Crossroad
Own them, or take something off the table?
These Stocks Get Benefit of the Doubt
Market backtracks on skepticism over biotechs.
Market Rewards Biotech Latecomers
It shouldn't be possible, but it never seems too late to get in.
Jobs Report and Biotech Nerves
I am happy to be standing in for Doug Kass today on the Daily Diary. The market-moving event du jour is likely to be the jobs report, which hits an hour before the open. Hopefully it will show the American economy continues to add jobs at the same r...
That's Just What's Supposed to Happen
Stocks that stabilized yesterday were terrific today.
Value in Good Management
Kroger is a good example of execution.
Recommended Reading, Part Deux
In Jim "El Capitan" Cramer's "Return of the Cult Stocks," he talks about comebacks in Tesla (TSLA), Facebook (FB), Netflix (NFLX), Amazon (AMZN) and others -- even Ali Blah Blah (BABA) and GoPro (GPRO) have had a rally, albeit from depressed levels....
Cramer: Return of the Cult Stocks
The cult of the buyer stays devoted to Tesla, Netflix, Amazon and more.
China Cuts Growth Target
And four other things you need to know now.
Dynavax Technologies: A New 'Best Idea'
This vaccine maker is now closer to several important milestones.
Why I Favor Big-Cap Growth Stocks
Because now is not the time to get complacent in this market.
From the Street of Dreams
Deutsche Bank reiterates its Buy recommendation on Gilead (GILD) (price target $125) based on the company's exclusive agreement with AbbVie (ABBV) for its HCV drug.
The Biotechs Are Back
Watch this leadership group that's been lagging.
There Are Still a Few Bargains Around
They're in the tech, pharma and biotechnology sectors.
Getting Defensive Now
I am adding allocation to healthcare.
Why I'm Sticking With Biotech
They offer a nice shelter for the headwinds now hitting equities.
Gilead Is Set to Surge
Its hepatitis C drug will dominate the market.
Gilead Is a Buying Opportunity
Its hepatitis C drug is better; the stock trades at a discount.
Heed the Rotation
Stocks that do well when the economy rises are shining.
